Nautilus Neurosciences and Tribute Pharma claimed that a new, water-soluble, buffered diclofenac potassium powder – Cambia is the only prescription non – steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.
Engineered using Dynamic Buffering Technology (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research, Cambia is specifically designed for fast, effective relief from the symptoms of migraine.
Cambia is approved in the US for the acute treatment of migraine with or without aura and was launched in the US in June 2010.
Nautilus Neurosciences chairman and CEO James Fares said that Canada is an important pharmaceutical market and opportunity for Cambia.
"This partnership along with recent developments in the US has significantly enhanced our ability to market Cambia to the broader North American market and reach more people suffering from acute migraine headaches," Fares said.
"We look forward to completing the expansion of our efforts through the addition of a partner for the family practice market in the US in 2011."
Tribute Pharma president and CEO Rob Harris said that Tribute Pharma is very excited about the potential for Cambia in Canada and that they look forward to building a partnership with Nautilus Neurosciences.